Hi, Shrewd!        Login  
Shrewd'm.com 
A merry & shrewd investing community
 Best Of BRK.A | Best Of | Favourites & Replies | All Boards | Post of the Week!
Search BRK.A
Shrewd'm.com Merry shrewd investors
Best Of BRK.A | Best Of | Favourites & Replies | All Boards | Post of the Week!
Search BRK.A

Stocks A to Z / Stocks B / Berkshire Hathaway (BRK.A)
Unthreaded | Threaded | Whole Thread (2) |
Author: LucidDreamer   😊 😞
Number: of 15056 
Subject: PR tied to their EU partner
Date: 10/02/2024 4:04 PM
Post New | Post Reply | Report Post | Recommend It!
No. of Recommendations: 6
https://www.esperion.com/news-releases/news-releas...

“This real-world study adds to the body of clinical evidence and further underscores the therapeutic role for bempedoic acid in helping patients achieve their LDL-C goals, which is particularly important as cardiovascular disease remains the number one cause of death in Europe and the United States,” said Sheldon Koenig, President and CEO of Esperion. “We are very pleased with DSE’s continued progress and look at successes in the growing adoption of bempedoic acid in Europe and other international markets as a potential proxy for the significant market opportunity in the United States.”

Dreamer
Post New | Post Reply | Report Post | Recommend It!
Print the post
Unthreaded | Threaded | Whole Thread (2) |


Announcements
Berkshire Hathaway FAQ
Contact Shrewd'm
Contact the developer of these message boards.

Ticker or Board Name Author

Best Of BRK.A | Best Of | Favourites & Replies | All Boards | Followed Shrewds